메뉴 건너뛰기




Volumn 7, Issue 1, 2015, Pages 1-13

Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; ANTIBODY; IMMUNOGLOBULIN G; PLACEBO;

EID: 84928569750     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-015-0108-3     Document Type: Article
Times cited : (118)

References (32)
  • 2
    • 84872119357 scopus 로고    scopus 로고
    • Alzheimer Disease International. The worldwide economic impact of dementia 2010
    • 23305821 e3
    • Wimo A, Jönsson L, Bond J, Prince M, Winblad B. Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9:1-11. e3.
    • (2013) Alzheimers Dement , vol.9 , pp. 1-11
    • Wimo, A.1    Jönsson, L.2    Bond, J.3    Prince, M.4    Winblad, B.5
  • 3
    • 43049129669 scopus 로고    scopus 로고
    • Treatment options in Alzheimer's disease: maximizing benefit, managing expectations
    • 1:CAS:528:DC%2BD1cXltFOkt7k%3D 18391487
    • Farlow MR, Miller ML, Pejovic V. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord. 2008;25:408-22.
    • (2008) Dement Geriatr Cogn Disord , vol.25 , pp. 408-422
    • Farlow, M.R.1    Miller, M.L.2    Pejovic, V.3
  • 4
    • 84894122063 scopus 로고    scopus 로고
    • Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial
    • 4086818 1:CAS:528:DC%2BC2cXjtVWrsL0%3D 24549548
    • Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311:682-91.
    • (2014) JAMA , vol.311 , pp. 682-691
    • Porsteinsson, A.P.1    Drye, L.T.2    Pollock, B.G.3    Devanand, D.P.4    Frangakis, C.5    Ismail, Z.6
  • 5
    • 78650210590 scopus 로고    scopus 로고
    • Immunotherapy for Alzheimer's disease
    • 3074967 1:CAS:528:DC%2BC3MXhsFKms7s%3D 21158978
    • Morgan D. Immunotherapy for Alzheimer's disease. J Intern Med. 2011;269:54-63.
    • (2011) J Intern Med , vol.269 , pp. 54-63
    • Morgan, D.1
  • 6
    • 0034700471 scopus 로고    scopus 로고
    • Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
    • 1:CAS:528:DC%2BD3MXhslWitg%3D%3D 11140685
    • Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979-82.
    • (2000) Nature , vol.408 , pp. 979-982
    • Janus, C.1    Pearson, J.2    McLaurin, J.3    Mathews, P.M.4    Jiang, Y.5    Schmidt, S.D.6
  • 7
    • 70049083865 scopus 로고    scopus 로고
    • 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
    • 1:CAS:528:DC%2BD1MXhtFGktLzF 18294736
    • Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009;30:1728-36.
    • (2009) Neurobiol Aging , vol.30 , pp. 1728-1736
    • Relkin, N.R.1    Szabo, P.2    Adamiak, B.3    Burgut, T.4    Monthe, C.5    Lent, R.W.6
  • 8
    • 4644275963 scopus 로고    scopus 로고
    • Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease
    • 1738770 1:STN:280:DC%2BD2cvpvFyqsA%3D%3D 15377700
    • Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, et al. Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004;75:1472-4.
    • (2004) J Neurol Neurosurg Psychiatry , vol.75 , pp. 1472-1474
    • Dodel, R.C.1    Du, Y.2    Depboylu, C.3    Hampel, H.4    Frölich, L.5    Haag, A.6
  • 9
    • 0033536163 scopus 로고    scopus 로고
    • Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
    • 1:CAS:528:DyaK1MXks1Khsbc%3D 10408445
    • Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-7.
    • (1999) Nature , vol.400 , pp. 173-177
    • Schenk, D.1    Barbour, R.2    Dunn, W.3    Gordon, G.4    Grajeda, H.5    Guido, T.6
  • 10
    • 48949085739 scopus 로고    scopus 로고
    • Amyloid-β immunisation for Alzheimer's disease
    • 2752661 1:CAS:528:DC%2BD1cXhtFWmsLrJ 18667360
    • Wisniewski T, Konietzko U. Amyloid-β immunisation for Alzheimer's disease. Lancet Neurol. 2008;7:805-11.
    • (2008) Lancet Neurol , vol.7 , pp. 805-811
    • Wisniewski, T.1    Konietzko, U.2
  • 11
    • 79959670013 scopus 로고    scopus 로고
    • The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects
    • 1:CAS:528:DC%2BC3MXos1yisrs%3D 21697382
    • Wiessner C, Wiederhold KH, Tissot AC, Frey P, Danner S, Jacobson LH, et al. The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011;31:9323-31.
    • (2011) J Neurosci , vol.31 , pp. 9323-9331
    • Wiessner, C.1    Wiederhold, K.H.2    Tissot, A.C.3    Frey, P.4    Danner, S.5    Jacobson, L.H.6
  • 12
    • 0033835996 scopus 로고    scopus 로고
    • Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
    • 1:CAS:528:DC%2BD3cXlsFamtL4%3D 10932230
    • Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916-9.
    • (2000) Nat Med , vol.6 , pp. 916-919
    • Bard, F.1    Cannon, C.2    Barbour, R.3    Burke, R.L.4    Games, D.5    Grajeda, H.6
  • 14
    • 84892748542 scopus 로고    scopus 로고
    • Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease
    • 1:CAS:528:DC%2BC2cXhs1Ggt70%3D 24450890
    • Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311-21.
    • (2014) N Engl J Med , vol.370 , pp. 311-321
    • Doody, R.S.1    Thomas, R.G.2    Farlow, M.3    Iwatsubo, T.4    Vellas, B.5    Joffe, S.6
  • 15
    • 84892695519 scopus 로고    scopus 로고
    • Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease
    • 4159618 1:CAS:528:DC%2BC2cXhs1Ggt7o%3D 24450891
    • Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322-33.
    • (2014) N Engl J Med , vol.370 , pp. 322-333
    • Salloway, S.1    Sperling, R.2    Fox, N.C.3    Blennow, K.4    Klunk, W.5    Raskind, M.6
  • 16
    • 10744230547 scopus 로고    scopus 로고
    • Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
    • 1:CAS:528:DC%2BD3sXks1OktLk%3D 12847155
    • Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology. 2003;61:46-54.
    • (2003) Neurology , vol.61 , pp. 46-54
    • Orgogozo, J.M.1    Gilman, S.2    Dartigues, J.F.3    Laurent, B.4    Puel, M.5    Kirby, L.C.6
  • 17
    • 84862331908 scopus 로고    scopus 로고
    • Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
    • 1:CAS:528:DC%2BC38XovVygsr0%3D 22677258
    • Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012;11:597-604.
    • (2012) Lancet Neurol , vol.11 , pp. 597-604
    • Winblad, B.1    Andreasen, N.2    Minthon, L.3    Floesser, A.4    Imbert, G.5    Dumortier, T.6
  • 18
    • 84862777153 scopus 로고    scopus 로고
    • Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
    • 4063417 1:CAS:528:DC%2BC38XislSqs74%3D 22305802
    • Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11:241-9.
    • (2012) Lancet Neurol , vol.11 , pp. 241-249
    • Sperling, R.1    Salloway, S.2    Brooks, D.J.3    Tampieri, D.4    Barakos, J.5    Fox, N.C.6
  • 20
    • 0021271971 scopus 로고
    • Clinical diagnosis of Alzheimer disease: report of the NINCDS-ADRDA work group under the auspices of Department Of Health And Human Services Task Force on Alzheimer's disease
    • 1:STN:280:DyaL2c3ks1altQ%3D%3D 6610841
    • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer disease: report of the NINCDS-ADRDA work group under the auspices of Department Of Health And Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-44.
    • (1984) Neurology , vol.34 , pp. 939-944
    • McKhann, G.1    Drachman, D.2    Folstein, M.3    Katzman, R.4    Price, D.5    Stadlan, E.M.6
  • 21
    • 84903309463 scopus 로고    scopus 로고
    • Stability of anti-immunotherapeutic antibodies in frozen human serum samples
    • 1:CAS:528:DC%2BC2cXhtVenu7nE 24958123
    • Michaut L, Laurent N, Kentsch K, Spindeldreher S, Deckert-Salva F. Stability of anti-immunotherapeutic antibodies in frozen human serum samples. Bioanalysis. 2014;6:1395-407.
    • (2014) Bioanalysis , vol.6 , pp. 1395-1407
    • Michaut, L.1    Laurent, N.2    Kentsch, K.3    Spindeldreher, S.4    Deckert-Salva, F.5
  • 22
    • 0141751616 scopus 로고    scopus 로고
    • Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study
    • 14550701
    • Chan D, Janssen JC, Whitwell JL, Watt HC, Jenkins R, Frost C, et al. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet. 2003;362:1121-2.
    • (2003) Lancet , vol.362 , pp. 1121-1122
    • Chan, D.1    Janssen, J.C.2    Whitwell, J.L.3    Watt, H.C.4    Jenkins, R.5    Frost, C.6
  • 23
    • 2542502430 scopus 로고    scopus 로고
    • ApoE genotype accounts for the vast majority of AD risk and AD pathology
    • 1:CAS:528:DC%2BD2cXksVGgtLw%3D 15172743
    • Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 2004;25:641-50.
    • (2004) Neurobiol Aging , vol.25 , pp. 641-650
    • Raber, J.1    Huang, Y.2    Ashford, J.W.3
  • 24
    • 0027503277 scopus 로고
    • Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age
    • 1:STN:280:DyaK3s3itlOhsg%3D%3D 8467819
    • Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Långström G, et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol. 1993;33:129-33.
    • (1993) Eur Neurol , vol.33 , pp. 129-133
    • Blennow, K.1    Fredman, P.2    Wallin, A.3    Gottfries, C.G.4    Karlsson, I.5    Långström, G.6
  • 25
    • 84895729926 scopus 로고    scopus 로고
    • Amyloid-β-directed immunotherapy for Alzheimer's disease
    • 4238820 1:CAS:528:DC%2BC2cXkt12iu7w%3D 24605809
    • Lannfelt L, Relkin NR, Siemers ER. Amyloid-β-directed immunotherapy for Alzheimer's disease. J Intern Med. 2014;275:284-95.
    • (2014) J Intern Med , vol.275 , pp. 284-295
    • Lannfelt, L.1    Relkin, N.R.2    Siemers, E.R.3
  • 26
    • 72149123967 scopus 로고    scopus 로고
    • Total and phosphorylated tau protein as biological markers of Alzheimer's disease
    • 2815003 1:CAS:528:DC%2BD1MXhsFynt7nN 19853650
    • Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp Gerontol. 2010;45:30-40.
    • (2010) Exp Gerontol , vol.45 , pp. 30-40
    • Hampel, H.1    Blennow, K.2    Shaw, L.M.3    Hoessler, Y.C.4    Zetterberg, H.5    Trojanowski, J.Q.6
  • 29
    • 47149112621 scopus 로고    scopus 로고
    • 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
    • 1:CAS:528:DC%2BD1cXoslWkt74%3D 18640458
    • 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216-23.
    • (2008) Lancet , vol.372 , pp. 216-223
    • Holmes, C.1    Boche, D.2    Wilkinson, D.3    Yadegarfar, G.4    Hopkins, V.5    Bayer, A.6
  • 31
    • 77950805621 scopus 로고    scopus 로고
    • Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nature Rev Neurol. 2010;6:108-19. A published erratum appears in Nat
    • Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nature Rev Neurol. 2010;6:108-19. A published erratum appears in Nat. Rev Neurol. 2010;6:183.
    • (2010) Rev Neurol , vol.6 , pp. 183
    • Lemere, C.A.1    Masliah, E.2
  • 32
    • 84895729886 scopus 로고    scopus 로고
    • Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014
    • 3956752 1:STN:280:DC%2BC2crhsFaqug%3D%3D 24605808
    • Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, et al. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med. 2014;275:251-83.
    • (2014) J Intern Med , vol.275 , pp. 251-283
    • Schneider, L.S.1    Mangialasche, F.2    Andreasen, N.3    Feldman, H.4    Giacobini, E.5    Jones, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.